US20150011584A1 - Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors - Google Patents

Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors Download PDF

Info

Publication number
US20150011584A1
US20150011584A1 US14/355,153 US201214355153A US2015011584A1 US 20150011584 A1 US20150011584 A1 US 20150011584A1 US 201214355153 A US201214355153 A US 201214355153A US 2015011584 A1 US2015011584 A1 US 2015011584A1
Authority
US
United States
Prior art keywords
day
donepezil
connexin
acid
combination product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/355,153
Other languages
English (en)
Inventor
Franck Mouthon
Mathieu Charveriat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Assigned to COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES reassignment COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHARVERIAT, MATHIEU, MOUTHON, FRANCK
Publication of US20150011584A1 publication Critical patent/US20150011584A1/en
Priority to US15/903,662 priority Critical patent/US10765670B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • This invention relates to improvements in therapeutic neurological and neuropsychic treatments using acetylcholinesterase inhibitors. More specifically, the invention enables the effects of acetylcholinesterase inhibitors to be potentiated by certain molecules, referred to here as connexin-blocking agents.
  • Cognitive disorders are a category of mental health disorders that primarily affect learning, memory, perception, and problem solving, and include amnesia, dementia, and delirium. Causes vary between the different types of disorders but most include damage to the memory portions of the brain. Treatments depend on how the disorder is caused. Medication and therapies are the most common treatments; however, for some types of disorders such as certain types of amnesia, treatments can suppress the symptoms but there is currently no cure.
  • Enhancement of cognitive function occurs when the action of Acetylcholine (Ach) is increased via inhibition of its metabolizing enzymes, principally the acetylcholinesterase enzyme (AChE). Accordingly, the strategy of increasing cholinergic activity to restore cognitive functions has been a primary and enduring therapeutic tactic.
  • ChEIs acetylcholinesterase inhibitors
  • AChEIs or anti-cholinesterase agents have been shown to reduce the rate at which acetylcholine is broken down and hence increase its concentration in the brain (thereby combating the loss of ACh caused by the death of the cholinergic neurons).
  • Acetylcholinesterase inhibitors enhance neuronal transmission by increasing the availability of ACh in muscarinic and nicotinic receptors.
  • these ChEIs may have psychotropic effects and may play an important role in controlling neuropsychiatric and behavioral disturbances in patients with cognitive disorders. These agents may also contribute to the management of other disorders with cholinergic system abnormalities and neuropsychiatric symptoms such as visual hallucinations.
  • Donepezil is a well-known AChEI. It has been proposed for treating numerous cognitive disorders (Lewy body dementia, vascular dementia, sleep apnea, mild cognitive impairment, schizophrenia, CADASIL syndrome, attention deficit disorder, postcoronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome). It has been approved for treating mild to moderate Alzheimer's disease.
  • AD Alzheimer's disease
  • brain cells neurotrophic factor
  • senile dementia which is the mental deterioration (loss of intellectual ability) that is associated with old age. They are currently 5.3 million people with AD in the United States, and more than half of these individuals will likely be categorized as having moderate or severe disease.
  • AD Alzheimer's disease
  • acetylcholinesterase-inhibitors that have been approved so far (and in particular donepezil), have been less promising therapeutically as they produce only modest improvements in cognitive function and the induced cognitive gain (if any) only lasts few months.
  • the present invention fulfills this need by disclosing a new therapeutic product showing improved effects on memory loss than the existing treatments.
  • FIG. 1 shows the ⁇ -hippocampal analysis of adult mice (4-5 month old mice—6 first columns) and elderly mice (17-18 month-old mice—6 last columns) after intraperitoneal administration of 0.1 mg/kg or 0.3 mg/kg of donepezil (DZP) associated or not with 1 mg/kg of meclofenamic acid (MFA).
  • DZP donepezil
  • MFA meclofenamic acid
  • FIG. 2 shows the total alternation of elderly mice (17-18 month-old mice) after intraperitoneal administration of NaCl (vehicle) or of 0.1 mg/kg, 0.3 mg/kg or 1 mg/kg of donepezil alone (DZP) or of 1 mg/kg of meclofenamic acid alone (MFA) or of the combination MFA and DZP (last column). Alternation has been recorded in a T-maze device.
  • FIG. 3 shows the alternation of “elderly” mice by blocks of two consecutive trials, after intraperitoneal administration of NaCl (vehicle), donepezil alone (0.1 mg/kg), MFA alone (1 mg/kg) and a combination of donepezil and MFA (last group of columns).
  • MFA Meclofenamic Acid
  • Meclofenamic acid has been described as a “connexin-blocking” agent having a non-steroidal anti-inflammatory activity.
  • a “connexin-blocking” agent is a chemical molecule, a protein, a protein fragment or a nucleic acid (for example RNAi) capable of inhibiting the functional activity of connexins, directly and/or indirectly, and more generally any type of intercellular junctions, and/or capable of functionally inhibiting, directly and/or indirectly any cellular activity involving a connexin-type protein.
  • RNAi nucleic acid
  • fenamates include the following compounds: meclofenamic acid, mefenamic acid, flufenamic acid, niflumic acid and tolfenamic acid. These compounds all have a non-steroidal anti-inflammatory activity, but this activity is not responsible for their capacity to block the gap junctions. It has indeed been suggested that the fenamates instead establish a direct interaction with the connexins or with the protein membrane interfaces that may influence the conformation of the connexins and therefore the functional role thereof (Harks E G, The Journal of Pharmacology and Experimental Therapeutics 2001 September, 298(3): 1033-41).
  • Benzoic 2-[(2,6-di-chloro-3-phenyl)amino]acid is a non-steroidal anti-inflammatory agent and a peripheral analgesic of the fenamate class, a prostaglandin inhibitor, described among the water-soluble blockers as being one of the most effective for reversibly blocking the gap junctions.
  • meclofenamic acid is not specific to a type of connexin and is therefore effective for blocking a large number of cerebral connexins (Pan F, Vis Neurosciences 2007, Jul.-Aug.; 24(4): 609-18).
  • Glycyrrhetinic acid derivatives refer to 18- ⁇ -glycyrrhetinic acid (BGA) also known as “enoxolone”, 18- ⁇ -glycyrrhetinic acid and carbenoxolone acid, which are triterpinoid saponins known for inhibiting the 11-hydroxysteroid dehydrogenase enzyme. Moreover, these compounds are capable of very effectively inhibiting the gap junctions (Pan F, Vis Neurosciences 2007, Jul.-Aug.; 24(4): 609-18).
  • quinine members of the quinine family, such as mefloquine (LARIAM), quinine and quinidine, also have a strong antagonist power on the gap junctions (Srinivas M, PNAS 2001, 98: 10942-10947; Pan F, Vis Neurosciences 2007, Jul.-Aug.; 24(4):609-18).
  • anesthetic agents such as halothane, enflurane and isoflurane, have a rapid and reversible gap junction blocking effect (Burt J M, et al, Circ Research. 1989; 65: 829-37).
  • oleamide cis-9-octadecenamide
  • the first amide of oleic acid also has an inhibiting action on the connexin molecules 43 and 32 (Guan X. et al, J. Cell Biol 1997; 139: 1785-92).
  • cyclodextrins ( ⁇ -cyclodextrin ( ⁇ -CD), ⁇ -cyclodextrin (( ⁇ -CD) and ⁇ -cyclodextrin ( ⁇ -CD)), which are natural cyclical oligosaccharides of ⁇ -D-glucopyranose, have proven anti-connexin properties (Locke D. et al, J. Biol Chem 2004; 279: 22883-92).
  • Lipophilic agents and fatty acids such as oleic acid, palmitoleic acid, decaenoic acid and myristoleic acid, the PKC inhibitor staurosporine, cardiac glycosides such as strophanthidin and ouabin, delta-9-tetrahydrocannabinol, 2-aminoethoxydiphenyl borate acetic acid and propionic acid, 12-O-tetradecanoylphorbol-13-acetate (TPA), 2,3 butandione monoxime, carbachol, noradrenaline, FGF-2, angiotensin-II, Atrial Natriuretic factor ANF, VEGF, 1-oleyl-2-acetyl-sn-glycerol, 11,12-epoxyeicosatrienoic acid, lidocaine, tonabersat, Nexagon and Peptagon (from CoDa Therapeutics) have been also proposed as acutely uncoupling cardiovascular gap junctions (Dhein S., Cardiovascular Research,
  • 2-aminoethyldiphenyl borate (2-APB) is a compound recently identified as a gap junction-blocking agent (Bai D, J Pharmacol Exp Ther, 2006 December; 319(3): 1452-8).
  • This modulator of the inositol 1,4,5-triphosphate receptor however fairly specifically targets certain connexins, such as connexins 26, 30, 36, 40, 45 and 50 (Bai D, J Pharmacol Exp Ther, 2006 December; 319(3): 1452-8).
  • the peptides corresponding to the extracellular sequences include the conserved patterns QPG and SHVR of E1 (Gap26) and the conserved pattern SRPTEK of E2 (Gap27) of the connexins are more effective for blocking the gap junctions (Chaytor A T et al, J. Physiol 1997; 503: 99-110).
  • the formation of functional gap junctions can be regulated by means of connexin phosphorylation.
  • phosphorylation of certain protein domains of the hexamer sub-units leads to an inhibition in the functionality of the gap junctions, according to the phosphorylation site, by closing the channels or by reducing the presence at the membrane (modification of traffic and half-life of sub-units) (Scemes E, Glia 2008 Jan. 15, 56(2): 145-53; Postma F R, J Cell Biol 1998 Mar. 9, 140(5): 1199-209; Shaw R M, Cell 2007, Feb. 9, 128(3): 547-60; Fabrizi G M, Brain 2007 February, 130 (Pt2): 394-403).
  • molecules can have an indirect gap junction-blocking effect, via the phosphorylation levels of the connexins.
  • They are in particular: lysophosphatidic acid, thrombin and neuropeptides, such as endothelin (Postma F R, J Cell Biol 1998 Mar. 9, 140(5): 1199-209).
  • the connexin-blocking agent has an indirect effect on the connexins and the gap junctions, and it is chosen from the group consisting of: lysophosphatidic acid, thrombin and neuropeptides, such as endothelin.
  • the connexin-blocking agents are advantageously chosen from: long-chain alcohols (for example, heptanol and octanol), fenamates (for example, meclofenamic acid, mefenamic acid, flufenamic acid, niflumic acid, tolfenamic acid), arylaminobenzoates, aminosulfonates (for example taurine), glycyrrhetinic acid derivatives (for example, 18- ⁇ -glycyrrhetinic acid, 18- ⁇ -glycyrrhetinic acid and carbenoxolone), oleamides (for example, cis-9-octadecenamide), or tetraalkylammonium ions and polyamines (such as spermine and spermidine), quinine derivatives (such as mefloquine, quinine, quinidine), 2-ABP, anesthetic agents (
  • the anti-inflammatory molecules can indirectly produce, by their action on the prostaglandin synthase, a structural modification of the connexins (the regulation of the connexin expression levels or of the phosphorylation thereof occurs in particular via PI3K and PKA, themselves dependent on the activity levels of Cox, NO and PG synthetase, targets of anti-inflammatories).
  • This modification in the sense of a reduction in the presence of the connexins in the junctions, indirectly causes a reduction in the functional activity of the connexins similar to a direct blocking of the connexins.
  • anti-connexin agents such as meclofenamic acid have no effect on Cox, NO and PG synthetase, and exhibit only an anti-connexin activity which is independent of these enzymes.
  • the present invention thus relates to a new combination product containing at least one connexin-blocking agent and an acetylcholinesterase inhibitor, as combination products for simultaneous, separate or sequential use over time, in patients suffering from cognitive disorders.
  • the connexin-blocking agent can advantageously improve the therapeutic effect of acetylcholinesterase inhibitors prescribed by physicians for treating a patient suffering from cognitive disorders.
  • the said connexin-blocking agent has been described above.
  • it is chosen in the group including: meclofenamic acid, mefenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, 18- ⁇ -glycyrrhetinic acid also known as “enoxolone”, 18- ⁇ -glycyrrhetinic acid, carbenoxolone acid, mefloquine, quinine, quinidine, oleamide (cis-9-octadecenamide), oleic acid, palmitoleic acid, decaenoic acid, myristoleic acid, staurosporine, cyclodextrins ( ⁇ -cyclodextrin ( ⁇ -CD), ⁇ -cyclodextrin (( ⁇ -CD) and ⁇ -cyclodextrin ( ⁇ -CD)), tonabersat (SB-220453, (cis-( ⁇ )-6-
  • meclofenamic acid mefloquine
  • 18- ⁇ -glycyrrhetinic acid carbenoxolone
  • said connexin-blocking agent is meclofenamic acid (MFA).
  • acetylcholinesterase inhibitor (often abbreviated as “AChEI”) or “anti-cholinesterase” is a chemical compound that inhibits the cholinesterase enzyme from breaking down acetylcholine, increasing both the level and duration of action of the neurotransmitter acetylcholine. They occur naturally as venoms and poisons and are used medicinally to treat myasthenia gravis, glaucoma, Alzheimer's disease, Levy body Dementia or as an antidote to anticholinergic poisoning.
  • the combination product of the invention differs from the prior art in that it contains, as active principles, a cholinergic agent (which is not an acetylcholinergic effector but an acetylcholinesterase inhibitor), and a connexin-blocking agent.
  • the combination product of the invention contains, as sole active principles, said acetylcholinesterase inhibitor and said connexin-blocking agent.
  • the combination product preferably does not contain effective amount of a ketone body precursor such as medium chain triglycerides having 5-12 carbon chains.
  • PDE7 phosphodiesterase 7 inhibitor
  • it does not contain effective amount of axomadol.
  • composition can, in addition to the two active principles, comprise any pharmaceutical vehicle, stabilizer, adjuvant and the like as frequently used in the art.
  • pharmaceutically acceptable vehicles include (but are not limited to): water; aqueous vehicles such as, but not limited to, sodium chloride solution, Ringer's solution, dextrose solution, dextrose and sodium chloride solution, and lactated Ringer's solution; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and nonaqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • aqueous vehicles such as, but not limited to, sodium chloride solution, Ringer's solution, dextrose solution, dextrose and sodium chloride solution, and lactated Ringer's solution
  • water-miscible vehicles such
  • this composition is formulated for oral administration (including buccal cavity or sublingually).
  • Other interesting formulations include formulations for intraperitoneal (i.p), intravenous (i.v.), subcutaneous (s.c.), intramuscular (i.m.), transcutaneous, transdermal, intrathecal and intracranial administrations.
  • Still other formulations include epidural, submucosal, intranasal, ocular cul-de-sac and rectal routes of administration, as well as administration by pulmonary inhalation. The skilled person well knows which vehicles can be used in each kind of composition.
  • a variety of administration means including but not limited to capsules, tablets, syrups, creams and ointments, suppositories, patches or any reservoir capable of containing and dispensing the two active principles, can be used for formulating the above-described compositions.
  • the skilled person well knows which vehicles can be used in each case.
  • said acetylcholinesterase inhibitor is chosen from Acephate, Azinphos-methyl, Bensulide, Cadusafos, Chlorethoxyfos, Chlorfenvinphos, Chlorpyrifos, Chlorpyrifos-Methyl, Coumaphos, Cyclosarin, Demeton, Demeton-S-Methyl, Diazinon, Dichlorvos, Dicrotophos, Diisopropyl fluorophosphate (Guthion), Diisopropylphosphate, Dimethoate, Dioxathion, Disulfoton, EA-3148, Echothiophate, Ethion, Ethoprop, Fenamiphos, Fenitrothion, Fenthion, Fosthiazate, Isofluorophate, Isoxathion, Malaoxon, Malathion, Methamidophos, Methidathion, Metrifonate, Mevinphos, Mono
  • Said acetylcholinesterase inhibitor can have reversible or irreversible effects.
  • said acetylcholinesterase inhibitor is an irreversible acetylcholinesterase inhibitor chosen among: Acephate, Azinphos-methyl, Bensulide, Cadusafos, Chlorethoxyfos, Chlorfenvinphos, Chlorpyrifos, Chlorpyrifos-Methyl, Coumaphos, Cyclosarin, Demeton, Demeton-S-Methyl, Diazinon, Dichlorvos, Dicrotophos, Diisopropyl fluorophosphate (Guthion), Diisopropylphosphate, Dimethoate, Dioxathion, Disulfoton, EA-3148, Echothiophate, Ethion, Ethoprop, Fenamiphos, Fenitrothion, Fenthion, Fosthiazate, Isofluorophate, Isoxathion, Malaoxon, Malathion, Methamidophos, Methid
  • said acetylcholinesterase inhibitor is a reversible acetylcholinesterase inhibitor chosen among: Aldicarb, Bendiocarb, Bufencarb, Carbaryl, Carbendazim, Carbetamide, Carbofuran, Chlorbufam, Chloropropham, Ethienocarb, Ethiofencarb, Fenobucarb, Fenoxycarb, Formetanate, Furadan, Ladostigil, Methiocarb, Methomyl, Miotine, Oxamyl, Phenmedipham, Pinmicarb, Pirimicarb, Propamocarb, Propham, Propoxur, Ganstigmine, Neostigmine, Phenserine and its enantiomer Posiphen, Physostigmine, Pyridostigmine, Rivastigmine, eptastigmine (heptylphysostigmine), Acotiamide, Ambenonium, Don
  • said acetylcholinesterase inhibitor is chosen among: ER 127528 (1-(3-fluorobenzyl)-4-[(2-fluoro-5,6-dimethoxy-1-indanone-2-yl)methyl]piperidine hydrochlo-ride), thiatolserine, RS 1259 (N,N-dimethylcarbamic acid 4-[1 (S)-(methylamino)-3-(4 nitrophenoxy)propyl]phenyl ester hemifumarate), ipidacrine (NIK-247), velnacrine (9-Amino-1,2,3,4-tetrahydro-1-acridinol), eptastigmine (heptylphysostigmine), zifrosilone (2,2,2-trifluoro-1-[3-(tri-methylsilyl)phenyl]ethanone), T 82 (2-[2-(1-benzylpiperidin-4-yl)ethy
  • said acetylcholinesterase inhibitor is donepezil, a reversible acetylcholinesterase inhibitor, or a pharmaceutically salt thereof.
  • pharmaceutically acceptable salt for example a salt obtained by mineral or organic acid addition of basic residues such as amines; alkali or organic addition of acidic residues such as carboxylic acids and combinations comprising one or more of the foregoing salts.
  • the pharmaceutically acceptable salts include non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; other acceptable inorganic salts include metal salts such as sodium salt, potassium salt, cesium salt, and the like; and alkaline earth metal salts, such as calcium salt, magnesium salt, and the like, and combinations comprising one or more of the foregoing salts.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • other acceptable inorganic salts include metal salts such as sodium salt, potassium salt, cesium salt, and the like
  • alkaline earth metal salts such as calcium salt, magnesium salt, and the like, and combinations comprising one or more of the foregoing salts.
  • Organic salts includes salts prepared from organic acids such as acetic, trifluoroacetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC—(CH 2 ) n —COOH where n is 0-4, and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt, and the like; and amino
  • Donepezil (2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-i-nden-1-one) is a piperidine-based reversible, noncompetitive ChEI, which is indicated in the management of patients with Alzheimer's disease of mild to moderate severity.
  • Donepezil has been proposed for treating numerous other cognitive disorders (vascular dementia, sleep apnea, mild cognitive impairment, schizophrenia, the CADASIL syndrome, attention deficit disorder, post coronary cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome).
  • the present invention targets in particular a therapeutic substance combination product containing at least one connexin-blocking agent and one acetylcholinesterase inhibitor (AChEI), wherein said connexin-blocking agent is meclofenamic acid and wherein said acetylcholinesterase inhibitor (AChEI) is donepezil or a pharmaceutical salt thereof.
  • connexin-blocking agent is meclofenamic acid
  • said acetylcholinesterase inhibitor (AChEI) is donepezil or a pharmaceutical salt thereof.
  • the present invention targets a therapeutic substance combination product containing at least one connexin-blocking agent and an acetylcholinesterase inhibitor (AChEI), as combination products for simultaneous, separate or sequential use, as a medicament for treating patients suffering from cognitive disorders, wherein said connexin-blocking agent is meclofenamic acid and wherein said acetylcholinesterase inhibitor (AChEI) is donepezil or a pharmaceutical salt thereof.
  • connexin-blocking agent is meclofenamic acid
  • said acetylcholinesterase inhibitor (AChEI) is donepezil or a pharmaceutical salt thereof.
  • This combination product is for example a kit, containing, either in the same recipient or in two distinct recipients, MFA and donepezil or a pharmaceutical salt thereof.
  • the combination product of the invention contains preferably 1 ⁇ g/kg/day to 1 mg/kg/day of donepezil or a pharmaceutical salt thereof. In a preferred embodiment, the combination product of the invention contains between 100 ⁇ g/kg/day and 1 mg/kg/day, and even more preferably between 250 ⁇ g/kg/day and 1 mg/kg/day of donepezil or a pharmaceutical salt thereof. At these high doses, the combination with MFA enables to prolong the effect of donepezil during time, and to avoid secondary effects that often occur when such high doses are used.
  • the combination product of the invention contains between 1 ⁇ g/kg/day and 100 ⁇ g/kg/day, more preferably between 10 ⁇ g/kg/day and 100 ⁇ g/kg/day, and even more preferably between 10 ⁇ g/kg/day and 40 ⁇ g/kg/day of donepezil or a pharmaceutical salt thereof.
  • the combination with MFA enables to obtain a sufficient effect of donepezil without triggering secondary effects.
  • MFA anti-inflammatory factor
  • a dose of approximately 5 mg/kg/day see Wagner C. et al, Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 2007; R1781-6.
  • the amount of MFA is much lower, and typically comprised between 0.5 ⁇ g/kg/day and 0.5 mg/kg/day, more preferably between 25 ⁇ g/kg/day and 0.5 mg/kg/day, and even more preferably between 125 ⁇ g/kg/day and 0.5 mg/kg/day.
  • This combination product differs from the prior art in that, due to the very low doses of MFA which are used, it does not affect the accumulation of the A ⁇ proteins (A ⁇ 38 , A ⁇ 40 or A ⁇ 42 ) and it does not involve the cyclooxygenase (COX) pathway.
  • MFA non-steroid-anti-inflammatory drug
  • NSAID non-steroid-anti-inflammatory drug
  • MFA especially administrated at a low dose, potentiates donepezil and lead to an unexpected synergistic effect: although it has no effect on its own at this low dose, MFA indeed enhances the effect of donepezil beyond what was thought to be its maximal effect (Bontempi B., et al, Neuropsychopharmacology 28 2003; 1235-46). Also, MFA accelerates the donepezil's effect, which is observed as soon as 30 minutes post-treatment, while it is not expected before three-day post-treatment when administered alone (see for example in Joo Y. et al, Molecular Pharmacology 2006; 69:76-84).
  • the term ⁇ cognitive disorder>> means any condition characterized by a deficit in mental activities associated with thinking, learning, or memory. Examples of such disorders include agnosias, amnesias, aphasias, apraxias, deliriums, dementias, and learning disorders.
  • the cause of a cognitive disorder may be unknown or uncertain.
  • the cognitive disorder may be associated with (that is, be caused by or occur in the presence of) other conditions characterized by damage to or loss of neurons or other structures involved in the transmission of signals between neurons.
  • cognitive disorders may be associated with neurodegenerative diseases such as Alzheimer's disease, corticobasal degeneration, Creutzfeldt-Jacob disease, frontotemporal lobar degeneration, Huntington's disease, multiple sclerosis, normal pressure hydrocephalus, organic chronic brain syndrome, Parkinson's disease, Pick disease, progressive supranuclear palsy, or senile dementia (Alzheimer type); it may be associated with trauma to the brain, such as that caused by chronic subdural hematoma, concussion, intracerebral hemorrhage, or with other injury to the brain, such as that caused by infection (e.g., encephalitis, meningitis, septicemia) or drug intoxication or abuse; and may be associated with Down syndrome and Fragile X syndrome.
  • neurodegenerative diseases such as Alzheimer's disease, corticobasal degeneration, Creutzfeldt-Jacob disease, frontotemporal lobar degeneration, Huntington's disease, multiple sclerosis, normal pressure hydroce
  • Cognitive disorders may also be associated with other conditions which impair normal functioning of the central nervous system, including psychiatric disorders such as mild cognitive disorder, postcoronary bypass cognitive impairment, CADASIL syndrome, anxiety disorders, dissociative disorders, mood disorders, schizophrenia, and somatoform and factitious disorders; it may also be associated with conditions of the peripheral nervous system, such as chronic pain and neuropathic pain.
  • psychiatric disorders such as mild cognitive disorder, postcoronary bypass cognitive impairment, CADASIL syndrome, anxiety disorders, dissociative disorders, mood disorders, schizophrenia, and somatoform and factitious disorders
  • dementias are: AIDS dementia complex, Binswanger's disease, dementia with Lewy Bodies, frontotemporal dementia, multi-infarct dementia, Pick's disease, semantic dementia, senile dementia, sleep apnea in dementia, and vascular dementia.
  • learning disorders are: Asperger's syndrome, attention deficit disorder, attention deficit hyperactivity disorder, autism, childhood disintegrative disorder, and Rett syndrome.
  • aphasia are progressive non-fluent aphasia.
  • the combination product of the invention enables to treat the particular cognitive disorders chosen from: Alzheimer's disease, Parkinson's disease, vascular dementia and senile dementia.
  • this invention also relates to the use of this combination product, simultaneously, separately or sequentially, in patients suffering from cognitive disorders.
  • the two components of the treatment are administered to the patient simultaneously.
  • the two components can be packaged together, in the form of a mixture, or separately, then mixed spontaneously before being administered together to the patient. More commonly, the two components are administered simultaneously, but separately. They can for example be administered with an interval of time which is typically comprised between few minutes and several hours, preferably between 1 minute and five hours, more preferably between 1 minute and two hours.
  • the routes of administration of the two components may be different.
  • the administration can also be performed at different sites.
  • the two components are administered sequentially or spaced apart over time, for example in the same day or at an interval ranging from several hours to several weeks, or even several months.
  • the present invention also involves the use of at least one connexin-blocking agent such as MFA for preparing a drug intended to be administered before, at the same time, or after an acetylcholinesterase inhibitor, such as donepezil, in order to treat a patient suffering from cognitive disorders.
  • at least one connexin-blocking agent such as MFA
  • an acetylcholinesterase inhibitor such as donepezil
  • the invention includes the use of at least one connexin-blocking agent such as MFA, for potentiating the effect of an acetylcholinesterase inhibitor such as donepezil in patients suffering from cognitive disorders.
  • MFA connexin-blocking agent
  • an acetylcholinesterase inhibitor such as donepezil
  • the present invention also targets the use of at least one connexin-blocking agent such as MFA, for potentiating the effect of an acetylcholinesterase inhibitor such as donepezil in patients suffering from cognitive disorders.
  • MFA connexin-blocking agent
  • an acetylcholinesterase inhibitor such as donepezil
  • the invention thus includes a connexin-blocking agent such as MFA for use to potentiate the effect of an acetylcholinesterase inhibitor such as donepezil in patients suffering from cognitive disorders.
  • a connexin-blocking agent such as MFA for use to potentiate the effect of an acetylcholinesterase inhibitor such as donepezil in patients suffering from cognitive disorders. All the embodiments concerning the acetylcholinesterase inhibitor, the connexin-blocking agent and the cognitive disorders are hereby encompassed.
  • the present invention also targets a method for potentiating the effect of an acetylcholinesterase inhibitor such as donepezil, in patients suffering from cognitive disorders, said method using at least one connexin-blocking agent, for example MFA.
  • an acetylcholinesterase inhibitor such as donepezil
  • the term “potentiate” in this case means significantly increasing the effects of the cholinergic agent administered before, simultaneously or after the anti-connexin agent.
  • the combination of the cholinergic agent with the anti-connexin agent makes it possible to enhance the therapeutic effect of said cholinergic agent, to an extend which is higher than that obtained by the cholinergic agent alone, whatever its concentration is considered.
  • a “significant increase” of the effects of the cholinergic agent is obtained for example when this effect is enhanced by at least about 25%, preferably at least about 40% and more preferably by at least about 50% as compared with the effect of the cholinergic agent alone.
  • Said effect can be for example measured by analyzing the EEG profile or the percentage of alternation relative to vehicles in laboratory animals as described in the experimental part below.
  • This enhanced effect also enables to reduce the doses at which said cholinergic agent is used, and therefore to limit the potential adverse effects of said cholinergic agent, and/or to reduce the effects of failure and withdrawal.
  • the invention therefore also relates to the use of at least one connexin-blocking agent, for reducing the doses of said cholinergic agent and/or limiting the adverse effects of said cholinergic agent, and/or reducing the effects of failure and withdrawal.
  • Donepezil is typically used at a dose comprised between 5 mg to 10 mg per day for an adult individual, which means approximately between 100 ⁇ g/kg/day and 200 ⁇ g/kg/day.
  • the combination of the invention enables either to reduce the said doses, typically to less than 100 ⁇ g/kg/day and preferably to less than 50 ⁇ g/kg/day (for example, the dose of donepezil can be comprised between 1 ⁇ g/kg/day and 100 ⁇ g/kg/day, preferably between 10 ⁇ g/kg/day and 100 ⁇ g/kg/day, and more preferably between 10 ⁇ g/kg/day and 40 ⁇ g/kg/day) or to maximize the effect of donepezil over time without inducing secondary effects (when donepezil is used at higher doses, that is, between 100 ⁇ g/kg/day and 1 mg/kg/day, preferably between 100 ⁇ g/kg/day and 200 ⁇ g/kg/day, or between 250 ⁇ g/kg/day and
  • the invention describes a method for treating a patient suffering from cognitive disorders, including the administration to said patient of:
  • mice Two groups of male C57bl/6 mice (seven mice from 4 to 5 month old and seven mice from 17 to 18 month old) were pre-implanted with bilateral hippocampal bipolar electrodes under isoflurane anaesthesia. A two-week period of recovery was realized before recordings.
  • mice per treatment Different intraperitoneal treatments were performed by circular combination of 7 mice per treatment (donepezil 0.1 and 0.3 mg/kg, meclofenamic 1 mg/kg, donepezil 0.1 mg/kg+MFA 1 mg/kg).
  • the dose of 1 mg/kg of MFA has previously been described as not affecting the electroencephalographic signal in rodents.
  • EEG measures were performed on different batches of awoke mice (previously implanted and tamed) by recordings two hours after injection.
  • the spectral analysis is carried out by Fourier transform (FFT) and allows the calculation of the relative powers for each Hertz and each second. FFT data are then averaged minute by minute and reported to control solvent recording realized on the day before in strictly identical experimental conditions.
  • the spectral powers of two hippocampal electrodes are then averaged between 3 and 12 Hertz and represented hourly.
  • the alternating sequential test is widely used to assess spatial working memory in mice (Beracochea D. J. and Jaffard R., Behav. Neurosci. 101 (1987) 187-97).
  • Spontaneous alternation is the innate tendency of rodents to alternate their choices to enter into the compartments of arrival of a T-maze device, over successive trials.
  • N To alternate during a given trial N, the animal must remember the choice made selectively in test N ⁇ 1, so the decline in alternating will reflect the phenomenon of oblivion.
  • the response in alternating is performance measure. Sequential alternating assess more specifically the sensitivity to interference, a major factor in oblivion.
  • mice of 17 to 18 months (“elderly” mice) were intraperitoneally injected with a solution of NaCl (vehicle), donepezil (DZP), meclofenamic acid (MFA) or a combination of these two latter compounds, 30 minutes before T-maze experiment.
  • NaCl vehicle
  • DZP donepezil
  • MFA meclofenamic acid
  • mice Thirty minutes after treatment (NaCl, donepezil, MFA), “elderly” mice are placed in the T-maze device. The percentage of alternation was measured for 7 consecutive trials, 50% corresponding to a random alternation. Results are shown on FIGS. 2 and 3 (**: p ⁇ 0.01; *: p ⁇ 0.05 (ANOVA)).
  • Donepezil is a promnesiant molecule described as improving the performance of mice in T-maze devices (Spowart-Manning L., Behav. Brain. Res. 151 (2004) 37-46).
  • the combination with meclofenamic acid allows to reach a higher effect (almost 85%) than the maximal effect observed for donepezil alone, and for a lesser dose of donepezil (0.1 mg/kg, see FIG. 2 , last column).
  • the combination with meclofenamic acid allows to obtain a higher mnesic interference resistance than the one induced by donepezil. This improvement of the effect of donepezil has never been observed so far.
  • EEG results are expressed as the relative power of hippocampal theta rhythm of each group compared to vehicles injected mice.
  • SA-task results are expressed as the mean percentage of alternation relative to vehicles over the seven trials. *: p ⁇ 0.05; **: p ⁇ 0.01.
  • meclofenamic acid modifies the pharmacological profile of donepezil, modifying the temporal evolution and intensity of its effects on memory.
  • MFA during acute treatment, has no own effect on the preclinical model used herein, so that MFA's activity is thought to be independent from A ⁇ accumulation:
  • the preclinical model used herein is a pathological model of cognitive impairment which is not characterized by an A ⁇ accumulation. Indeed, there is no A ⁇ accumulation in wild-type mice, even beyond 24 months (see FIG. 2 in Walther T. et al, PLoS One 2009; e4590), although a cognitive decline is depicted at 17-18 months (see in Beracochea D. et al, Psychopharmacology (Berl) 193 2007; 63-73). In addition, no cognitive significant effect of MFA is seen at 1 mg/kg alone, ( FIGS. 2 and 3 of this application) while such dose potentiate donepezil.
  • MFA for its anti-Cox activity MFA is administrated at dose above 5 mg/kg (see in Wagner C. et al, Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 2007; R1781-6). However, MFA was used in the present invention at a dose lower than those published for its NSAID activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US14/355,153 2011-10-31 2012-10-31 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors Abandoned US20150011584A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/903,662 US10765670B2 (en) 2011-10-31 2018-02-23 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306407.5 2011-10-31
EP11306407.5A EP2586436A1 (en) 2011-10-31 2011-10-31 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
PCT/EP2012/071631 WO2013064579A1 (en) 2011-10-31 2012-10-31 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/071631 A-371-Of-International WO2013064579A1 (en) 2011-10-31 2012-10-31 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/903,662 Continuation US10765670B2 (en) 2011-10-31 2018-02-23 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
US20150011584A1 true US20150011584A1 (en) 2015-01-08

Family

ID=47080551

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/355,153 Abandoned US20150011584A1 (en) 2011-10-31 2012-10-31 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors
US15/903,662 Expired - Fee Related US10765670B2 (en) 2011-10-31 2018-02-23 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/903,662 Expired - Fee Related US10765670B2 (en) 2011-10-31 2018-02-23 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors

Country Status (14)

Country Link
US (2) US20150011584A1 (pt)
EP (3) EP2586436A1 (pt)
JP (1) JP6053805B2 (pt)
CN (1) CN103906511B (pt)
AU (2) AU2012331136B2 (pt)
CA (1) CA2853325C (pt)
DK (1) DK2773337T3 (pt)
ES (1) ES2701048T3 (pt)
HR (1) HRP20182043T8 (pt)
HU (1) HUE042671T2 (pt)
IL (2) IL232292A0 (pt)
PL (1) PL2773337T3 (pt)
PT (1) PT2773337T (pt)
WO (1) WO2013064579A1 (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10111860B1 (en) * 2016-01-15 2018-10-30 Aristea Translational Medicine Corporation Compositions and methods for treating concussion
US10864192B2 (en) * 2016-01-15 2020-12-15 Aristea Translational Medicine Corporation Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG158153A1 (en) * 2004-12-21 2010-01-29 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
PL3024458T3 (pl) * 2013-07-24 2018-08-31 Commissariat à l'énergie atomique et aux énergies alternatives Zastosowanie flekainidu jako środka anty-koneksynowego oraz sposób wzmacniania efektów działania leku psychotropowego
US11103473B2 (en) * 2013-09-06 2021-08-31 Asdera Llc Treatment and prevention of autism and autism spectrum disorders
CA2989052C (en) * 2015-06-15 2020-11-24 Rush Unversity Medical Center Brain derived ppar.alpha. ligands
WO2019067269A2 (en) 2017-09-28 2019-04-04 Asdera Llc USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DISRUPTION
EP3593822A1 (en) 2018-07-13 2020-01-15 Theranexus Therapeutic and diagnostic applications of a new method of monitoring of neuroglial interaction memri)
FR3110393B1 (fr) 2020-05-20 2022-05-06 Grn Consulting Compose et composition pour induire une neuroprotection
FR3128872B1 (fr) 2021-11-08 2024-09-13 Rest Therapeutics Nouvelles combinaisons synergiques a base de fenm

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1251499A (en) 1997-11-26 1999-06-15 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
DE10119862A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
WO2004091522A2 (en) 2003-04-11 2004-10-28 Myriad Genetics, Inc. Method for treating neurodegenerative disorders
CA2508585A1 (en) * 2004-06-01 2005-12-01 Axonyx, Inc. Transdermal delivery system for treatment of cognitive disorders
HUP0401850A3 (en) 2004-09-15 2008-03-28 Egis Gyogyszergyar Nyilvanosan Donepezil salts for producing pharmaceutical composition
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
US8021701B1 (en) * 2005-04-13 2011-09-20 Perry Stephen C Composition to retard the onset of symptoms of alzheimer's disease
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
CN101991859A (zh) * 2009-10-27 2011-03-30 上海复旦复华药业有限公司 一种石杉碱甲的β-环糊精包合物及其制备方法和制剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10111860B1 (en) * 2016-01-15 2018-10-30 Aristea Translational Medicine Corporation Compositions and methods for treating concussion
US10864192B2 (en) * 2016-01-15 2020-12-15 Aristea Translational Medicine Corporation Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions

Also Published As

Publication number Publication date
IL270748B (en) 2021-10-31
JP2014532635A (ja) 2014-12-08
EP2773337A1 (en) 2014-09-10
PL2773337T3 (pl) 2019-04-30
DK2773337T3 (en) 2018-12-10
US10765670B2 (en) 2020-09-08
PT2773337T (pt) 2018-12-20
EP3446688A1 (en) 2019-02-27
IL270748A (en) 2020-01-30
HUE042671T2 (hu) 2019-07-29
ES2701048T3 (es) 2019-02-20
CN103906511B (zh) 2016-04-06
CA2853325A1 (en) 2013-05-10
CA2853325C (en) 2021-08-24
US20180177773A1 (en) 2018-06-28
CN103906511A (zh) 2014-07-02
JP6053805B2 (ja) 2016-12-27
HRP20182043T8 (hr) 2019-06-14
EP2773337B1 (en) 2018-09-19
EP2586436A1 (en) 2013-05-01
AU2012331136B2 (en) 2017-06-29
HRP20182043T1 (hr) 2019-04-19
AU2012331136A1 (en) 2014-05-01
AU2017228472B2 (en) 2019-07-11
WO2013064579A1 (en) 2013-05-10
AU2017228472A1 (en) 2017-10-05
IL232292A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
US10765670B2 (en) Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors
Paris et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier
ES2521494T3 (es) Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
EP0668763B1 (en) Use of phenserine for the preparation of medicaments for the treatment of cognitive disorders
US10881665B2 (en) Formulations for treatment of post-traumatic stress disorder
WO1998030243A1 (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer&#39;s disease
Tokita et al. Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats
US9233109B2 (en) Compositions, methods of use, and methods of treatment
Lazartigues et al. Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat
US20180360845A1 (en) Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
US9492543B2 (en) Compositions for treating cognitive disorders
WO2014204956A1 (en) Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (mci), early dementia, a-synucleinopathy, traumatic brain injury, cardiomyopathy, eye disease and skin damage
US20190125734A1 (en) Composition for treating or preventing atopic dermatitis

Legal Events

Date Code Title Description
AS Assignment

Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOUTHON, FRANCK;CHARVERIAT, MATHIEU;REEL/FRAME:033790/0126

Effective date: 20140625

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION